4.7 Article

Genomic meta-analysis of growth factor and integrin pathways in chronic kidney transplant injury

Journal

BMC GENOMICS
Volume 14, Issue -, Pages -

Publisher

BMC
DOI: 10.1186/1471-2164-14-275

Keywords

Chronic rejection; NA Microarrays; Genomics; Growth factors; Integrins; Proteomics; Meta-analysis; Chronic Allograft Nephropathy /Tubular atrophy with interstitial fibrosis (CAN/IFTA); Kidney transplantation

Funding

  1. NIH [U19 AI52349]
  2. Molly Baber Research Fund
  3. Verna Harrah Research Fund
  4. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052349, R56AI052349] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Background: Chronic Allograft Nephropathy (CAN) is a clinical entity of progressive kidney transplant injury. The defining histology is tubular atrophy with interstitial fibrosis (IFTA). Using a meta-analysis of microarrays from 84 kidney transplant biopsies, we revealed growth factor and integrin adhesion molecule pathways differentially expressed and correlated with histological progression. A bioinformatics approach mining independent datasets leverages new and existing data to identify correlative changes in integrin and growth factor signaling pathways. Results: Analysis of CAN/IFTA Banff grades showed that hepatocyte growth factor (HGF), and epidermal growth factor (EGF) pathways are significantly differentially expressed in all classes of CAN/IFTA. MAPK-dependent pathways were also significant. However, the TGF beta pathways, albeit present, failed to differentiate CAN/IFTA progression. The integrin subunits beta 8, alpha v, alpha mu and beta 5 are differentially expressed, but beta 1, beta 6 and alpha 6 specifically correlate with progression of chronic injury. Results were validated using our published proteomic profiling of CAN/IFTA. Conclusions: CAN/IFTA with chronic kidney injury is characterized by expression of distinct growth factors and specific integrin adhesion molecules as well as their canonical signaling pathways. Drug target mapping suggests several novel candidates for the next generation of therapeutics to prevent or treat progressive transplant dysfunction with interstitial fibrosis.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available